Epigenetic mechanisms in diabetic vascular complications

Cardiovascular Research

Volumn 90, Issue 3, 2011, Pages 421-429

  Reddy, Marpadga A ^a   Natarajan, Rama ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Diabetes; Epigenetics; MicroRNA; Next generation sequencing; Vascular complications

Indexed keywords

DNA; DNA METHYLTRANSFERASE; HISTONE H3; MICRORNA;

ACETYLATION; ARTICLE; CELL ACTIVITY; CHROMATIN; DIABETES MELLITUS; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETICS; GLYCEMIC CONTROL; HUMAN; MEDICAL TECHNOLOGY; METABOLISM; METHYLATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; VASCULAR DISEASE;

ANIMALS; DIABETIC ANGIOPATHIES; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; MICRORNAS; MODELS, GENETIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; TRANSCRIPTION, GENETIC;

EID: 79957487252     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr024     Document Type: Article

References (159)

1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA 2002;287:2570-2581. (Pubitemid 34517204)
2. He Z, King GL. Microvascular complications of diabetes. Endocrinol Metab Clin North Am 2004;33:215-238. (Pubitemid 38438432)
3. Ziyadeh FN, Sharma K. Overview: Combating diabetic nephropathy. J Am Soc Nephrol 2003;14:1355-1357. (Pubitemid 36514676)
4. Natarajan R, Nadler JL. Lipid inflammatory mediators in diabetic vascular disease. Arterioscler Thromb Vasc Biol 2004;24:1542-1548. (Pubitemid 39180875)
5. King GL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol 2008;79:1527-1534.
6. Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2005;54:1615-1625. (Pubitemid 40770750)
7. Yan SF, Ramasamy R, Schmidt AM. Mechanisms of disease: Advanced glycation endproducts and their receptor in inflammation and diabetes complications. Nat Clin Pract 2008;4:285-293. (Pubitemid 351571138)
8. Marrero MB, Fulton D, Stepp D, Stern DM. Angiotensin II-induced signaling pathways in diabetes. Curr Diabetes Rev 2005;1:197-202.
9. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820. (Pubitemid 34000785)
10. Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995;44:1139-1146.
11. Natarajan R, Cai Q. Monocyte retention in the pathology of atherosclerosis. Future Cardiol 2005;1:331-340.
12. Averill MM, Bornfeldt KE. Lipids versus glucose in inflammation and the pathogenesis of macrovascular disease in diabetes. Curr Diab Rep 2009;9:18-25.
13. Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010;106:1319-1331.
14. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;84:489-497. (Pubitemid 29138585)
15. Reddy MA, Li SL, Sahar S, Kim YS, Xu ZG, Lanting L et al. Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells. J Biol Chem 2006;281:13685-13693. (Pubitemid 43855284)
16. Writing Team DCCT/EDIC Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563-2569.
17. Colagiuri S, Cull CA, Holman RR. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? U.K. prospective diabetes study 61. Diabetes Care 2002;25:1410-1417. (Pubitemid 41071154)
18. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653. (Pubitemid 41817713)
19. Ceriello A. Hypothesis: The ' memory', the new challenge of diabetes. Diabetes Res Clin Pract 2009;86(Suppl. 1):S2-S6.
20. Villeneuve LM, Natarajan R. The role of epigenetics in the pathology of diabetic complications. Am J Physiol 2010;299:F14-F25.
21. Pirola L, Balcerczyk A, Okabe J, El-Osta A. Epigenetic phenomena linked to diabetic complications. Nat Rev Endocrinol 2010;6:665-675.
22. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008;57:1349-1354.
23. Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 1987;36:808-812. (Pubitemid 17145301)
24. Hammes HP, Klinzing I, Wiegand S, Bretzel RG, Cohen AM, Federlin K. Islet transplantation inhibits diabetic retinopathy in the sucrose-fed diabetic Cohen rat. Invest Ophthalmol Vis Sci 1993;34:2092-2096. (Pubitemid 23148648)
25. Kowluru RA. Effect of reinstitution of good glycemic control on retinal oxidative stress and nitrative stress in diabetic rats. Diabetes 2003;52:818-823. (Pubitemid 36323591)
26. Chan PS, Kanwar M, Kowluru RA. Resistance of retinal inflammatory mediators to suppress after reinstitution of good glycemic control: Novel mechanism for metabolic memory. J Diabetes Complications 2010;24:55-63.
27. Roy S, Sala R, Cagliero E, Lorenzi M. Overexpression of fibronectin induced by diabetes or high glucose: Phenomenon with a memory. Proc Natl Acad Sci USA 1990;87: 404-408.
28. Ihnat MA, Thorpe JE, Kamat CD, Szabo C, Green DE, Warnke LA et al. Reactive oxygen species mediate a cellular 'memory' of high glucose stress signalling. Diabetologia 2007;50:1523-1531. (Pubitemid 46879013)
29. El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008;205:2409-2417.
30. Brasacchio D, Okabe J, Tikellis C, Balcerczyk A, George P, Baker EK et al. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 2009;58:1229-1236.
31. Li SL, Reddy MA, Cai Q, Meng L, Yuan H, Lanting L et al. Enhanced proatherogenic responses in macrophages and vascular smooth muscle cells derived from diabetic db/db mice. Diabetes 2006;55:2611-2619. (Pubitemid 44871163)
32. Villeneuve LM, Reddy MA, Lanting LL, Wang M, Meng L, Natarajan R. Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc Natl Acad Sci USA 2008;105: 9047-9052.
33. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell 2007; 128:707-719. (Pubitemid 46273570)
34. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997;389:251-260. (Pubitemid 27406632)
35. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010;31:27-36.
36. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol 2010;28:1057-1068.
37. Nightingale KP, O'Neill LP, Turner BM. Histone modifications: Signalling receptors and potential elements of a heritable epigenetic code. Curr Opin Genet Dev 2006; 16:125-136. (Pubitemid 43376058)
38. Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell 2007;128: 669-681. (Pubitemid 46273573)
39. Maunakea AK, Chepelev I, Zhao K, Bruneau B. Epigenome mapping in normal and disease States. Circ Res 2010;107:327-339.
40. Miranda TB, Jones PA. DNA methylation: The nuts and bolts of repression. J Cell Physiol 2007;213:384-390. (Pubitemid 47509717)
41. Wu SC, Zhang Y. Active DNA demethylation: Many roads lead to Rome. Nat Rev Mol Cell Biol 2010;11:607-620.
42. Kouzarides T. Chromatin modifications and their function. Cell 2007;128:693-705. (Pubitemid 46273577)
43. Lee DY, Teyssier C, Strahl BD, Stallcup MR. Role of protein methylation in regulation of transcription. Endocr Rev 2005;26:147-170.
44. Shilatifard A. Chromatin modifications by methylation and ubiquitination: Implications in the regulation of gene expression. Annu Rev Biochem 2006;75:243-269. (Pubitemid 44118033)
45. Zhang Y, Reinberg D. Transcription regulation by histone methylation: Interplay between different covalent modifications of the core histone tails. Genes Dev 2001;15:2343-2360. (Pubitemid 32899739)
46. Margueron R, Reinberg D. Chromatin structure and the inheritance of epigenetic information. Nat Rev Genet 2010;11:285-296.
47. Shi Y. Histone lysine demethylases: Emerging roles in development, physiology and disease. Nat Rev Genet 2007;8:829-833. (Pubitemid 47609092)
48. Pradhan S, Chin HG, Esteve PO, Jacobsen SE. SET7/9 mediated methylation of nonhistone proteins in mammalian cells. Epigenetics 2009;4:383-387.
49. Pons D, de Vries FR, van den Elsen PJ, Heijmans BT, Quax PH, Jukema JW. Epigenetic histone acetylation modifiers in vascular remodelling: New targets for therapy in cardiovascular disease. Eur Heart J 2009;30:266-277.
50. Ling C, Groop L. Epigenetics: A molecular link between environmental factors and type 2 diabetes. Diabetes 2009;58:2718-2725.
51. Pinney SE, Simmons RA. Epigenetic mechanisms in the development of type 2 diabetes. Trends Endocrinol Metab 2010;21:223-229.
52. Morgan HD, Sutherland HG, Martin DI, Whitelaw E. Epigenetic inheritance at the agouti locus in the mouse. Nat Genet 1999;23:314-318. (Pubitemid 29526429)
53. Park JH, Stoffers DA, Nicholls RD, Simmons RA. Development of type 2 diabetes following intrauterine growth retardation in rats is associated with progressive epigenetic silencing of Pdx1. J Clin Invest 2008;118:2316-2324. (Pubitemid 351872348)
54. Ling C, Del Guerra S, Lupi R, Ronn T, Granhall C, Luthman H et al. Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion. Diabetologia 2008;51:615-622.
55. Barres R, Osler ME, Yan J, Rune A, Fritz T, Caidahl K et al. Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density. Cell Metab 2009;10:189-198.
56. Brennan EP, Ehrich M, Brazil DP, Crean JK, Murphy M, Sadlier DM et al. DNA methylation profiling in cell models of diabetic nephropathy. Epigenetics 2010;5: 396-401.
57. Williams KT, Garrow TA, Schalinske KL. Type I diabetes leads to tissue-specific DNA hypomethylation in male rats. J Nutr 2008;138:2064-2069.
58. Bell CG, Teschendorff AE, Rakyan VK, Maxwell AP, Beck S, Savage DA. Genomewide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus. BMC Med Genomics 2010;3:33-42.
59. Hiltunen MO, Turunen MP, Hakkinen TP, Rutanen J, Hedman M, Makinen K et al. DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. Vasc Med 2002;7:5-11. (Pubitemid 34654067)
60. Laukkanen MO, Mannermaa S, Hiltunen MO, Aittomaki S, Airenne K, Janne J et al. Local hypomethylation in atherosclerosis found in rabbit ec-sod gene. Arterioscler Thromb Vasc Biol 1999;19:2171-2178. (Pubitemid 29422250)
61. Hiltunen MO, Yla-Herttuala S. DNA methylation, smooth muscle cells, and atherogenesis. Arterioscler Thromb Vasc Biol 2003;23:1750-1753. (Pubitemid 37254858)
62. Turunen MP, Aavik E, Yla-Herttuala S. Epigenetics and atherosclerosis. Biochim Biophys Acta 2009;1790:886-891.
63. Matouk CC, Marsden PA. Epigenetic regulation of vascular endothelial gene expression. Circ Res 2008;102:873-887. (Pubitemid 351591544)
64. Lund G, Andersson L, Lauria M, Lindholm M, Fraga MF, Villar-Garea A et al. DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E. J Biol Chem 2004;279:29147-29154. (Pubitemid 38915787)
65. Zaina S, Lindholm MW, Lund G. Nutrition and aberrant DNA methylation patterns in atherosclerosis: More than just hyperhomocysteinemia? J Nutr 2005;135:5-8. (Pubitemid 40094312)
66. Stenvinkel P, Karimi M, Johansson S, Axelsson J, Suliman M, Lindholm B et al. Impact of inflammation on epigenetic DNA methylation-a novel risk factor for cardiovascular disease? J Intern Med 2007;261:488-499. (Pubitemid 46587721)
67. Kim M, Long TI, Arakawa K, Wang R, Yu MC, Laird PW. DNA methylation as a biomarker for cardiovascular disease risk. PLoS One 2010;5:e9692.
68. Wilson VL, Jones PA. DNA methylation decreases in aging but not in immortal cells. Science 1983;220:1055-1057. (Pubitemid 13090144)
69. Chakrabarti SK, Francis J, Ziesmann SM, Garmey JC, Mirmira RG. Covalent histone modifications underlie the developmental regulation of insulin gene transcription in pancreatic beta cells. J Biol Chem 2003;278:23617-23623. (Pubitemid 36830183)
70. Deering TG, Ogihara T, Trace AP, Maier B, Mirmira RG. Methyltransferase Set7/9 maintains transcription and euchromatin structure at islet-enriched genes. Diabetes 2009;58:185-193.
71. Dhawan S, Tschen SI, Bhushan A. Bmi-1 regulates the Ink4a/Arf locus to control pancreatic beta-cell proliferation. Genes Dev 2009;23:906-911.
72. Musri MM, Carmona MC, Hanzu FA, Kaliman P, Gomis R, Parrizas M. Histone demethylase LSD1 regulates adipogenesis. J Biol Chem 2010;285:30034-30041.
73. Tateishi K, Okada Y, Kallin EM, Zhang Y. Role of Jhdm2a in regulating metabolic gene expression and obesity resistance. Nature 2009;458:757-761.
74. Gray SG, De Meyts P. Role of histone and transcription factor acetylation in diabetes pathogenesis. Diabetes Metab Res Rev 2005;21:416-433. (Pubitemid 41320653)
75. Haigis MC, Sinclair DA. Mammalian sirtuins: Biological insights and disease relevance. Annu Rev Pathol 2010;5:253-295.
76. Barnes PJ, Karin M. Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-1071. (Pubitemid 27163860)
77. Yerneni KK, Bai W, Khan BV, Medford RM, Natarajan R. Hyperglycemia- induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells. Diabetes 1999;48:855-864. (Pubitemid 29153087)
78. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y et al. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell 1999;97:889-901. (Pubitemid 29375048)
79. Guha M, Bai W, Nadler JL, Natarajan R. Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. J Biol Chem 2000;275:17728-17739. (Pubitemid 30430822)
80. Hatley ME, Srinivasan S, Reilly KB, Bolick DT, Hedrick CC. Increased production of 12/15 lipoxygenase eicosanoids accelerates monocyte/endothelial interactions in diabetic db/db mice. J Biol Chem 2003;278:25369-25375. (Pubitemid 36835286)
81. Shanmugam N, Reddy MA, Guha M, Natarajan R. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 2003;52:1256-1264. (Pubitemid 36523365)
82. Meng L, Park J, Cai Q, Lanting L, Reddy MA, Natarajan R. Diabetic conditions promote binding of monocytes to vascular smooth muscle cells and their subsequent differentiation. Am J Physiol Heart Circ Physiol 2009;298:H736-H745.
83. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010;72:219-246.
84. Vanden Berghe W, De Bosscher K, Boone E, Plaisance S, Haegeman G. The nuclear factor-kappaB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter. J Biol Chem 1999;274: 32091-32098.
85. Edelstein LC, Pan A, Collins T. Chromatin modification and the endothelial-specific activation of the E-selectin gene. J Biol Chem 2005;280:11192-11202. (Pubitemid 40418426)
86. Sahar S, Reddy MA, Wong C, Meng L, Wang M, Natarajan R. Cooperation of SRC-1 and p300 with NF-kappaB and CREB in angiotensin II-induced IL-6 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2007;27:1528-1534. (Pubitemid 46986106)
87. Reddy MA, Sahar S, Villeneuve LM, Lanting L, Natarajan R. Role of Src tyrosine kinase in the atherogenic effects of the 12/15-lipoxygenase pathway in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2009;29:387-393.
88. Fish JE, Matouk CC, Rachlis A, Lin S, Tai SC, D'Abreo C et al. The expression of endothelial nitric-oxide synthase is controlled by a cell-specific histone code. J Biol Chem 2005;280:24824-24838. (Pubitemid 40934573)
89. Rossig L, Li H, Fisslthaler B, Urbich C, Fleming I, Forstermann U et al. Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ Res 2002;91:837-844. (Pubitemid 35285082)
90. Dje N'Guessan P, Riediger F, Vardarova K, Scharf S, Eitel J, Opitz B et al. Statins control oxidized LDL-mediated histone modifications and gene expression in cultured human endothelial cells. Arterioscler Thromb Vasc Biol 2009;29:380-386.
91. Alkemade FE, van Vliet P, Henneman P, van Dijk KW, Hierck BP, van Munsteren JC et al. Prenatal exposure to apoE deficiency and postnatal hypercholesterolemia are associated with altered cell-specific lysine methyltransferase and histone methylation patterns in the vasculature. Am J Pathol 2010;176:542-548.
92. Miao F, Gonzalo IG, Lanting L, Natarajan R. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J Biol Chem 2004;279:18091-18097. (Pubitemid 38560579)
93. Miao F, Li S, Chavez V, Lanting L, Natarajan R. Coactivator-associated arginine methyltransferase-1 enhances nuclear factor-kappaB-mediated gene transcription through methylation of histone H3 at arginine 17. Mol Endocrinol 2006;20: 1562-1573. (Pubitemid 43967564)
94. Bode KA, Schroder K, Hume DA, Ravasi T, Heeg K, Sweet MJ et al. Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology 2007; 122:596-606. (Pubitemid 350075958)
95. Halili MA, Andrews MR, Labzin LI, Schroder K, Matthias G, Cao C et al. Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. J Leukoc Biol 2010;87:1103-1114.
96. Saccani S, Natoli G. Dynamic changes in histone H3 Lys 9 methylation occurring at tightly regulated inducible inflammatory genes. Genes Dev 2002;16:2219-2224. (Pubitemid 35013084)
97. De Santa F, Totaro MG, Prosperini E, Notarbartolo S, Testa G, Natoli G. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell 2007;130:1083-1094. (Pubitemid 47410272)
98. De Santa F, Narang V, Yap ZH, Tusi BK, Burgold T, Austenaa L et al. Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J 2009; 28:3341-3352.
99. Li Y, Reddy MA, Miao F, Shanmugam N, Yee JK, Hawkins D et al. Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-kappaB-dependent inflammatory genes. Relevance to diabetes and inflammation. J Biol Chem 2008; 283:26771-26781.
100. Miao F, Wu X, Zhang L, Yuan YC, Riggs AD, Natarajan R. Genome-wide analysis of histone lysine methylation variations caused by diabetic conditions in human monocytes. J Biol Chem 2007;282:13854-13863. (Pubitemid 47100501)
101. Miao F, Smith DD, Zhang L, Min A, FengW, Natarajan R. Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: An epigenetic study in diabetes. Diabetes 2008;57:3189-3198.
102. Zhong Q, Kowluru RA. Role of histone acetylation in the development of diabetic retinopathy and the metabolic memory phenomenon. J Cell Biochem 2010;110: 1306-1313.
103. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457-463. (Pubitemid 38715140)
104. Yun JM, Jialal I, Devaraj S. Epigenetic regulation of high glucose-induced proinflammatory cytokine production in monocytes by curcumin. J Nutr Biochem 2010; doi:10.1016/j.jnutbio.2010.03.014. Published online ahead of print 21 July 2010.
105. Sun G, Reddy MA, Yuan H, Lanting L, Kato M, Natarajan R. Epigenetic histone methylation modulates fibrotic gene expression. J Am Soc Nephrol 2010;21: 2069-2080.
106. Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell 2009;136: 215-233.
107. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009;10:704-714.
108. Kato M, Natarajan R. microRNA cascade in diabetic kidney disease: Big impact initiated by a small RNA. Cell Cycle 2009;8:3613-3614.
109. Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res 2008;79:581-588.
110. Muhonen P, Holthofer H. Epigenetic and microRNA-mediated regulation in diabetes. Nephrol Dial Transplant 2009;24:1088-1096.
111. Cordes KR, Srivastava D. MicroRNA regulation of cardiovascular development. Circ Res 2009;104:724-732.
112. Albinsson S, Suarez Y, Skoura A, Offermanns S, Miano JM, Sessa WC. MicroRNAs are necessary for vascular smooth muscle growth, differentiation, and function. Arterioscler Thromb Vasc Biol 2010;30:1118-1126.
113. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009;460: 705-710.
114. Xin M, Small EM, Sutherland LB, Qi X, McAnally J, Plato CF et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev 2009;23:2166-2178.
115. Boettger T, Beetz N, Kostin S, Schneider J, Kruger M, Hein L et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest 2009;119:2634-2647.
116. Liu X, Cheng Y, Zhang S, Lin Y, Yang J, Zhang C. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res 2009;104:476-487.
117. Anand S, Majeti BK, Acevedo LM, Murphy EA, Mukthavaram R, Scheppke L et al. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med 2010;16:909-914.
118. Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010;328:1566-1569.
119. Chen T, Huang Z, Wang L, Wang Y, Wu F, Meng S et al. MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDLstimulated monocyte/macrophages. Cardiovasc Res 2009;83:131-139.
120. Xiao C, Rajewsky K. MicroRNA control in the immune system: Basic principles. Cell 2009;136:26-36.
121. Forrest AR, Kanamori-Katayama M, Tomaru Y, Lassmann T, Ninomiya N, Takahashi Y et al. Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation. Leukemia 2010;24:460-466.
122. O'Connell RM, Kahn D, Gibson WS, Round JL, Scholz RL, Chaudhuri AA et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 2010;33:607-619.
123. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004;432:226-230. (Pubitemid 39545853)
124. Lovis P, Roggli E, Laybutt DR, Gattesco S, Yang JY, Widmann C et al. Alterations in microRNA expression contribute to fatty acid-induced pancreatic beta-cell dysfunction. Diabetes 2008;57:2728-2736.
125. Mi QS, He HZ, Dong Z, Isales C, Zhou L. microRNA deficiency in pancreatic islet cells exacerbates streptozotocin-induced murine autoimmune diabetes. Cell Cycle 2010;9:3127-3129.
126. Gallagher IJ, Scheele C, Keller P, Nielsen AR, Remenyi J, Fischer CP et al. Integration of microRNA changes in vivo identifies novel molecular features of muscle insulin resistance in type 2 diabetes. Genome Med 2010;2:9.
127. Shanmugam N, Reddy MA, Natarajan R. Distinct roles of heterogeneous nuclear ribonuclear protein K and microRNA-16 in cyclooxygenase-2 RNA stability induced by S100b, a ligand of the receptor for advanced glycation end products. J Biol Chem 2008;283:36221-36233.
128. Shan ZX, Lin QX, Deng CY, Zhu JN, Mai LP, Liu JL et al. miR-1/miR-206 regulate Hsp60 expression contributing to glucose-mediated apoptosis in cardiomyocytes. FEBS Lett 2010;584:3592-3600.
129. Kato M, Zhang J,Wang M, Lanting L, Yuan H, Rossi J et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci USA 2007;104:3432-3437. (Pubitemid 46364176)
130. Kato M, Putta S, Wang M, Yuan H, Lanting L, Nair I et al. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol 2009;11:881-889.
131. Wang B, Herman-Edelstein M, Koh P, Burns W, Jandeleit-Dahm K, Watson A et al. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes 2010;59: 1794-1802.
132. Kato M,Wang L, Putta S,Wang M, Yuan H, Sun G et al. Posttranscriptional upregulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-{beta}-induced collagen expression in kidney cells. J Biol Chem 2010;285:34004-34015.
133. Long J,Wang Y,WangW, Chang BH, Danesh FR. Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions. J Biol Chem 2010;285:23457-23465.
134. Villeneuve LM, Kato M, Reddy MA,Wang M, Lanting L, Natarajan R. Enhanced levels of microRNA-125b in vascular smooth muscle cells of diabetic db/db mice leads to increased inflammatory gene expression by targeting the histone methyltransferase Suv39h1. Diabetes 2010;59:2904-2915.
135. Ansorge WJ. Next-generation DNA sequencing techniques. Nat Biotechnol 2009;25: 195-203.
136. Metzker ML. Sequencing technologies-the next generation. Nat Rev Genet 2010;11: 31-46.
137. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 2008;5:621-628. (Pubitemid 351911867)
138. Wang Z, Gerstein M, Snyder M. RNA-Seq: A revolutionary tool for transcriptomics. Nat Rev Genet 2009;10:57-63.
139. Schones DE, Zhao K. Genome-wide approaches to studying chromatin modifications. Nat Rev Genet 2008;9:179-191. (Pubitemid 351271798)
140. Farnham PJ. Insights from genomic profiling of transcription factors. Nat Rev Genet 2009;10:605-616.
141. Hawkins RD, Hon GC, Ren B. Next-generation genomics: An integrative approach. Nat Rev Genet 2010;11:476-486.
142. Zilberman D, Henikoff S. Genome-wide analysis of DNA methylation patterns. Development 2007;134:3959-3965. (Pubitemid 350269413)
143. Rauch TA, Pfeifer GP. The MIRA method for DNA methylation analysis. Methods Mol Biol 2009;507:65-75.
144. Sorensen AL, Collas P. Immunoprecipitation of methylated DNA. Methods Mol Biol 2009;567:249-262.
145. Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, Sivachenko A et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 2008;454:766-770.
146. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009;462:315-322.
147. Gu H, Bock C, Mikkelsen TS, Jager N, Smith ZD, Tomazou E et al. Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolution. Nat Methods 2010;7:133-136.
148. Turner FB, Cheung WL, Cheung P. Chromatin immunoprecipitation assay for mammalian tissues. Methods Mol Biol 2006;325:261-272.
149. Ren B, Robert F, Wyrick JJ, Aparicio O, Jennings EG, Simon I et al. Genome-wide location and function of DNA binding proteins. Science 2000;290:2306-2309. (Pubitemid 32041573)
150. Huebert DJ, Kamal M, O'Donovan A, Bernstein BE. Genome-wide analysis of histone modifications by ChIP-on-chip. Methods 2006;40:365-369. (Pubitemid 44709632)
151. Heintzman ND, Hon GC, Hawkins RD, Kheradpour P, Stark A, Harp LF et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 2009;459:108-112.
152. Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA. A chromatin landmark and transcription initiation at most promoters in human cells. Cell 2007;130:77-88. (Pubitemid 47031323)
153. Miao F, Wu X, Zhang L, Riggs AD, Natarajan R. Histone methylation patterns are cell-type specific in human monocytes and lymphocytes and well maintained at core genes. J Immunol 2008;180:2264-2269.
154. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006;125:315-326.
155. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z et al. High-resolution profiling of histone methylations in the human genome. Cell 2007;129:823-837. (Pubitemid 46802390)
156. Marson A, Levine SS, Cole MF, Frampton GM, Brambrink T, Johnstone S et al. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell 2008;134:521-533.
157. Mikkelsen TS, Ku M, Jaffe DB, Issac B, Lieberman E, Giannoukos G et al. Genomewide maps of chromatin state in pluripotent and lineage-committed cells. Nature 2007;448:553-560. (Pubitemid 47206934)
158. Visel A, Blow MJ, Li Z, Zhang T, Akiyama JA, Holt A et al. ChIP-seq accurately predicts tissue-specific activity of enhancers. Nature 2009;457:854-858.
159. Human Epigenome Task Force. Moving AHEAD with an international human epigenome project. Nature 2008;454:711-715.